143 related articles for article (PubMed ID: 8188111)
1. [CA 125 in diagnosis and prognosis of epithelial ovarian cancer].
Cohen AD; Piura B; Cohen Y; Shoenfeld Y
Harefuah; 1994 Mar; 126(5):283-5, 303. PubMed ID: 8188111
[TBL] [Abstract][Full Text] [Related]
2. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
[TBL] [Abstract][Full Text] [Related]
4. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
5. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
6. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
Pearl ML; Yashar CM; Johnston CM; Reynolds RK; Roberts JA
Gynecol Oncol; 1994 Jun; 53(3):339-43. PubMed ID: 7911444
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
8. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565
[TBL] [Abstract][Full Text] [Related]
12. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
14. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
15. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma.
Gard GB; Houghton CR
Gynecol Oncol; 1994 Jun; 53(3):283-9. PubMed ID: 8206399
[TBL] [Abstract][Full Text] [Related]
16. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
Menczer J; Ben-Baruch G; Moran O; Lipitz S
Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
[TBL] [Abstract][Full Text] [Related]
17. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
18. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
19. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
20. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]